SVB Wealth LLC Sells 2,106 Shares of Stryker Corporation $SYK

SVB Wealth LLC lessened its position in shares of Stryker Corporation (NYSE:SYK) by 19.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,941 shares of the medical technology company’s stock after selling 2,106 shares during the period. SVB Wealth LLC’s holdings in Stryker were worth $3,143,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in shares of Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares in the last quarter. Schnieders Capital Management LLC. purchased a new position in Stryker in the 2nd quarter valued at approximately $205,000. Marshall Wace LLP raised its holdings in Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after acquiring an additional 77,831 shares during the period. Nebula Research & Development LLC purchased a new stake in shares of Stryker during the second quarter worth $219,000. Finally, HUB Investment Partners LLC purchased a new stake in shares of Stryker during the second quarter worth $253,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $285.49 on Monday. The stock has a market cap of $109.34 billion, a price-to-earnings ratio of 33.04, a PEG ratio of 1.80 and a beta of 0.80. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The business has a 50-day simple moving average of $340.37 and a 200 day simple moving average of $355.17. Stryker Corporation has a 52 week low of $284.95 and a 52 week high of $404.87.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same period in the previous year, the business earned $2.84 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Analyst Upgrades and Downgrades

SYK has been the subject of several recent research reports. Sanford C. Bernstein set a $410.00 price target on Stryker in a research report on Friday, May 1st. Wells Fargo & Company dropped their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $361.00 target price on shares of Stryker in a report on Friday, May 1st. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Finally, Leerink Partners began coverage on shares of Stryker in a report on Monday, April 13th. They issued an “outperform” rating and a $410.00 price target on the stock. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $395.48.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.